Medical Ikkou Group Co (TSE:3353) EBIT: 円2,127 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3353 Medical Ikkou Group Co Ltd TSE:3353
63 GF Score
Price 円2,841.00
GF Value 円3,534.01
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medical Ikkou Group Co EBIT?

Medical Ikkou Group Co TSE:3353 +0.53% 63 EBIT is 円2,127 Mil as of Feb. 2026. GuruFocus rates TSE:3353 with a GF Score™ of 63/100 and a GF Value™ of 円3,534.01 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Medical Ikkou Group Co's earnings before interest and taxes (EBIT) for the six months ended in Feb. 2026 was 円1,045 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was 円2,127 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medical Ikkou Group Co's annualized ROC % for the quarter that ended in Feb. 2026 was 5.35%. Medical Ikkou Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was 14.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medical Ikkou Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was 13.64%.

Medical Ikkou Group Co  (TSE:3353) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medical Ikkou Group Co's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=2088.856 * ( 1 - 36.95% )/( (23866.533 + 25323.773)/ 2 )
=1317.023708/24595.153
=5.35 %

where

Invested Capital(Q: Aug. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37914.044 - 6298.363 - ( 8599.566 - max(0, 12947.677 - 20696.825+8599.566))
=23866.533

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37576.117 - 6130.808 - ( 6121.536 - max(0, 11617.672 - 19146.409+6121.536))
=25323.773

Note: The Operating Income data used here is two times the semi-annual (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medical Ikkou Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2089.822/( ( (11041.202 + max(2852.92, 0)) + (10906.096 + max(4218.554, 0)) )/ 2 )
=2089.822/( ( 13894.122 + 15124.65 )/ 2 )
=2089.822/14509.386
=14.40 %

where Working Capital is:

Working Capital(Q: Aug. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8206.726 + 2368.895 + 1521.638) - (6298.363 + 0 + 2945.976)
=2852.92

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8373.09 + 2361.345 + 2290.438) - (6130.808 + 0 + 2675.511)
=4218.554

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medical Ikkou Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=2127.499/15595.446
=13.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Ikkou Group Co EBIT Related Terms

Medical Ikkou Group Co EBIT Historical Data

* Premium members only.

The historical data trend for Medical Ikkou Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Ikkou Group Co EBIT Chart

Medical Ikkou Group Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,534.73 1,364.57 1,716.68 1,965.44 2,127.50

Medical Ikkou Group Co Semi-Annual Data
Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Aug22 Feb23 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 916.49 1,163.57 801.87 1,082.59 1,044.91

TSE:3353 vs HON, MMM: EBIT Comparison

For the Conglomerates subindustry, Medical Ikkou Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Ikkou Group Co EV-to-EBIT vs Conglomerates Industry

For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medical Ikkou Group Co's EV-to-EBIT falls into.


TSE:3353
63GF Score
Medical Ikkou Group Co Ltd TSE:3353
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Ikkou Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円2,127 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円2,127 Mil mean?
Medical Ikkou Group Co (TSE:3353) has a EBIT of 円2,127 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medical Ikkou Group Co.
Is Medical Ikkou Group Co's EBIT too high?
Medical Ikkou Group Co's current EBIT is 円2,127 Mil. Overall, Medical Ikkou Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's EBIT compare to HON and MMM?
Medical Ikkou Group Co's EBIT of 円2,127 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Conglomerates company?
A good EBIT depends on the Conglomerates industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medical Ikkou Group Co. Medical Ikkou Group Co's current EBIT is 円2,127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,534.01, compared to a current price of 円2,841.00 — trading 19.6% below its estimated fair value. The current EBIT is 円2,127 Mil. Medical Ikkou Group Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current EBIT is 円2,127 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued. The current stock price of 円2,841.00 is trading 19.6% below its estimated GF Value™ of 円3,534.01. GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.

Key valuation signals for TSE:3353:

  • EBIT: 円2,127 Mil
  • GF Value™: 円3,534.01 vs. price of 円2,841.00 (19.6% below fair value)
  • GF Score™: 63/100 with 1 warning sign

No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Ikkou Group Co Business Description

Address 501 62 Fujikata, Mie Prefecture, Tsu, JPN, 514-0815
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
63GF Score

Get the complete analysis for TSE:3353

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,841.00
Price
円3,534.01
GF Value